ClinicalTrials.gg
RecruitingNCT06136546Updated Oct 27, 2026

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

A Phase 2 interventional study of Infliximab and Placebo in Depressive Disorder, Major and Inflammation, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 25 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Oct 27, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
25 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 88 studies in Depressive Disorder, Major by Massachusetts General Hospital — 9 open to participants now, 12 under way, none of them phase 3. Depressive Disorder, Major · Massachusetts General Hospital.

Planned enrollment
17th of 77
100 · median 40
Started
2025
with 1 other
Phase 2
14 of 88
3 open now
Primary completion
2028-08
later than 10 of 11 live
Registered
85th of 88
by date

Among the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, this one is the 17th largest by planned enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 in phase 2, reaches primary completion later than 10 of the 11 other live ones, and was the 85th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

9 of the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 25 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.

Read the detailed description

In this mechanistic RCT, depressed adults who exhibit a pro-inflammatory phenotype (C reactive protein ≥2mg/L) will be randomized on a 1:1 allocation to receive a TNF inhibitor (infliximab) or placebo. Over a two-week follow-up, participants will remotely complete brief, daily assessments of depressive symptoms and psychomotor speed/executive functioning using a mobile-based platform (TestMyBrain) in addition to in-person clinician-rated assessment of depressive symptom severity (Hamilton Depression Rating Scale), anhedonia (Dimensional Anhedonia Rating Scale), and more comprehensive computerized batteries assessing cognitive function (TestMyBrain). Blood will be drawn at baseline and week 1 to assess immune biomarkers (C reactive protein, tumor necrosis factor- alpha and its soluble receptors). Specifically, the study will determine whether randomization to infliximab is associated with improvement in psychomotor speed and executive function.

03

Conditions studied

  • Depressive Disorder, Major
  • Inflammation

Keywords

  • Depression
  • Major Depressive Disorder
  • Infliximab
  • Cognitive Dysfunction
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
25 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 25-50 years.
  2. Able to read and understand English and willing to provide /comply with the study protocol.
  3. Willingness to complete intravenous infusion and have blood drawn.
  4. Exhibit circulating blood level of C reactive protein ≥ 2mg/L at both screening and baseline visits.
  5. Diagnosed with Major Depressive Disorder.
  6. Moderate depressive symptom severity, as indicated by score ≥14 on the Hamilton Depression Rating Scale.
  7. Antidepressant treatment free for at least 4 weeks prior to study entry or be on a fixed treatment regimen for at least 4 weeks; willingness to continue treatment status (i.e., change/begin new treatment) until study termination.
  8. Willingness not to begin/change therapies until study termination (maximum of three weeks following screening).
  9. Be of non- per the following specific criteria:

    a. Non-childbearing potential (e.g., physiologically incapable of becoming pregnant, i.e., permanently sterilized (status post hysterectomy, bilateral tubal ligation), or is with her last menses at least one year prior to screening); or b. Childbearing potential and meets the following criteria: i. A negative serum pregnancy test within thirty days of infusion (may be repeated closer to infusion date at the discretion of the PI or study staff) and abstinent after the negative serum pregnancy test and prior to infusion; or ii. Using any form of hormonal , on hormone replacement therapy started prior to 12 months of amenorrhea, using an intrauterine device (IUD), having a monogamous relationship with a partner who has had a vasectomy, or is sexually abstinent; iii. Continuously use one of the following methods of birth control over the last six months: implants, injectable or patch hormonal contraception, oral contraceptives, IUD, double-barrier contraception, sexual abstinence.

Exclusion criteria

Exclusion Criteria:

  1. Medical conditions that could confound interpretation or increase participant risk, as indicated via medical history or laboratory testing; exclusionary medical conditions will include:

    i. acute injury/infection within one week of study initiation or infection within one month of study initiation that required antibiotic/antiviral treatment; or ii. chronic infection (e.g., or C or ) or history of Covid 19 infection within the past 6 months or with persisting symptoms; or iii. latent infection (e.g., tuberculosis, fungal infections), or history of recurrent infections; or iv. uncontrolled cardiovascular, endocrine, hematologic, hepatic, renal or neurologic disease (as determined by medical history, physical exam and laboratory testing); or v. cancer history; or vi. conditions; or vii. neurologic conditions (controlled) that substantially impacted cognitive function (e.g., stroke).

    Of note, stable medical conditions such as diabetes and cardiovascular disease, will be allowed in the study as they can contribute to endogenous inflammation.

  2. Active antipsychotic and anticonvulsant medication use (that interact with infliximab).
  3. Prior use of a TNF antagonist or use of systemic or anti-proliferative agents within 6 months of study entry.
  4. History of liver abnormalities.
  5. Major cognitive impairment as determined by study investigators.
  6. Active restrictive eating disorder or obsessive compulsive disorder deemed by study investigators to be primary cause of depressive disorder.
  7. History of a psychotic disorder or Bipolar disorder type I/II.
  8. Current substance use disorder (i.e., present in last six months), of greater than mild severity.
  9. Suicidal ideation based on a score ≥3 on the Columbia-Suicide Severity Rating Scale.
  10. Electroconvulsive therapy (ECT)/deep brain stimulation (DBS) within the last year, or report of persistent negative cognitive effects of ECT/DBS.
  11. Presence of a transplanted solid organ.
  12. Medication use affecting immune or cognitive function:

    i. Chronic use (>1 month) of a benzodiazepine more than the equivalent of 2 mg of lorazepam; or ii. Use of anti-inflammatory agents during the study: non-steroidal anti-inflammatory agents (NSAIDs) (excluding 81mg of aspirin), glucocorticoid containing medicines or statins, or cyclooxygenase-2 (COX-2) inhibitors; or iii. Anti-histamine use within 24-48 hours of cognitive testing; or iv. Use of topical steroids with a large area of application (more than the size of silver dollar coin); or v. Inhaled steroids taken more than 2-3 times per week.

  13. Considered by the study investigators to be inappropriate for the study due to safety concerns or to be unlikely to complete the protocol.
  14. History of allergic response to murine products.
  15. Received a within the last 6 weeks.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Infliximab

    Participants in this arm will receive 5 mg/kg of infliximab via an in-dwelling catheter.

    Drug: Infliximab

  • Placebo comparator
    Placebo

    Participants in this arm will receive saline as placebo via an in-dwelling catheter.

    Other: Placebo

Interventions

  • Intravenous infusion of infliximab

  • OtherPlacebo

    Intravenous infusion of saline solution (matching in color and consistency in infliximab)

06

What researchers measure

Primary outcomes

  1. Executive Function (TestMyBrain: Choice Reaction Time - Median Response Time on Correct Trials)

    Better within-person executive function performance (i.e. accuracy-adjusted response speed)

    Time frame: Repeated measures over two weeks

Secondary outcomes

  1. Hamilton Depression Rating Scale (17-item; range 0-54)

    Reduced depressive symptoms severity

    Time frame: Week 2

  2. Dimensional Anhedonia Rating Scale (17-item; range 0-68)

    Reduced anhedonia

    Time frame: Week 2

  3. Concentrations of circulating C reactive protein

    Reduced circulating C reactive protein

    Time frame: Week 1

  4. Processing Speed (TestMyBrain: Matching Shapes and Numbers - Number of Correct Responses)

    Total number of correct matches in the timed task

    Time frame: Repeated measures over two weeks

  5. Psychomotor Speed (TestMyBrain: Fast Reactions - Median Reaction Time)

    Median latency across valid responses, in milliseconds

    Time frame: Repeated measures over two weeks

  6. Self-reported Depressive Symptom Severity (PROMIS Short Form v1.0 - Depression 4a)

    Total score

    Time frame: Repeated measures over two weeks

  7. Self-reported Cognitive Difficulties (PDQ-20: Perceived Deficits Questionnaire)

    Total score on 20-item self-report measure developed to assess cognitive symptoms in major depressive disorder.

    Time frame: Week 2

  8. Self-reported Cognitive Difficulties (PROMIS v2.0 Cognitive Function 8a)

    Total score on 8-item self-report measure assessing perceived cognitive abilities in everyday life, including concentration, memory, and mental clarity.

    Time frame: Week 2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Aug 2028, 43 months after the start.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 43 months is above that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Nov 18, 2023
StartActual
Jan 23, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Jan 31, 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited; 3 exclusion criteria edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedExhibit circulating blood level of C reactive protein ≥ 3mg2mg/L at both screening and baseline visits.
  • EditedModerate depressive symptom severity, as indicated by score ≥1514 on the Hamilton Depression Rating Scale.
Exclusion criteria
  • Removedacute injury/infection within one week of study initiation or infection within one month of study initiation that required antibiotic/antiviral treatment ii. chronic infection (e.g., hepatitis B or C or HIV) or history of Covid 19 infection within the past 6 months or with persisting symptoms.
  • Editedacute injury/infection within one week of study initiation or infection within one month of study initiation that required antibiotic/antiviral treatment; or ii. chronic infection (e.g., hepatitis B or C or HIV) or history of Covid 19 infection within the past 6 months or with persisting symptoms; or iii. latent infection (e.g., tuberculosis, fungal infections), or history of recurrent infections,; or iv. uncontrolled cardiovascular, endocrine, hematologic, hepatic, renal or neurologic disease (as determined by medical history, physical exam and laboratory testing); or v. cancer history; or vi. autoimmune conditions; or vii. neurologic conditions (controlled) that are known to substantially impactimpacted cognitive function (e.g., stroke).
  • EditedPrior use of a TNF antagonist or use of systemic corticosteroids or anti-proliferative agents within one year6 months of study entry.
  • EditedChronic use (>1 month) of a benzodiazepine more than the equivalent of 2 mg of lorazepam; or ii. Use of anti-inflammatory agents during the study: non-steroidal anti-inflammatory agents (NSAIDs) (excluding 81mg of aspirin), glucocorticoid containing medicines or statins, or cyclooxygenase-2 (COX-2) inhibitors; or iii. Anti-histamine use within 24-48 hours of cognitive testing; or iv. Use of topical steroids with a large area of application (more than the size of silver dollar coin); or v. Inhaled steroids taken more than 2-3 times per week.
  • AddedReceived a live vaccine within the last 6 weeks.
Oct 27, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedExecutive Function (TestMyBrain: Choice Reaction Time - Median Response Time on Correct Trials)Time frame: Repeated measures over two weeks
  • RemovedPsychomotor Speed (TestMyBrain: Simple Reaction Time)Time frame: Repeated measures over two weeks
Oct 27, 2026
Secondary outcomes
5 added
What changed in the outcomes
  • AddedProcessing Speed (TestMyBrain: Matching Shapes and Numbers - Number of Correct Responses)Time frame: Repeated measures over two weeks
  • AddedPsychomotor Speed (TestMyBrain: Fast Reactions - Median Reaction Time)Time frame: Repeated measures over two weeks
  • AddedSelf-reported Depressive Symptom Severity (PROMIS Short Form v1.0 - Depression 4a)Time frame: Repeated measures over two weeks
  • AddedSelf-reported Cognitive Difficulties (PDQ-20: Perceived Deficits Questionnaire)Time frame: Week 2
  • AddedSelf-reported Cognitive Difficulties (PROMIS v2.0 Cognitive Function 8a)Time frame: Week 2
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Eligibility 2 inclusion criteria edited; 3 exclusion criteria edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedExhibit circulating blood level of C reactive protein ≥ 3mg2mg/L at both screening and baseline visits.
    • EditedModerate depressive symptom severity, as indicated by score ≥1514 on the Hamilton Depression Rating Scale.
    Exclusion criteria
    • Removedacute injury/infection within one week of study initiation or infection within one month of study initiation that required antibiotic/antiviral treatment ii. chronic infection (e.g., hepatitis B or C or HIV) or history of Covid 19 infection within the past 6 months or with persisting symptoms.
    • Editedacute injury/infection within one week of study initiation or infection within one month of study initiation that required antibiotic/antiviral treatment; or ii. chronic infection (e.g., hepatitis B or C or HIV) or history of Covid 19 infection within the past 6 months or with persisting symptoms; or iii. latent infection (e.g., tuberculosis, fungal infections), or history of recurrent infections,; or iv. uncontrolled cardiovascular, endocrine, hematologic, hepatic, renal or neurologic disease (as determined by medical history, physical exam and laboratory testing); or v. cancer history; or vi. autoimmune conditions; or vii. neurologic conditions (controlled) that are known to substantially impactimpacted cognitive function (e.g., stroke).
    • EditedPrior use of a TNF antagonist or use of systemic corticosteroids or anti-proliferative agents within one year6 months of study entry.
    • EditedChronic use (>1 month) of a benzodiazepine more than the equivalent of 2 mg of lorazepam; or ii. Use of anti-inflammatory agents during the study: non-steroidal anti-inflammatory agents (NSAIDs) (excluding 81mg of aspirin), glucocorticoid containing medicines or statins, or cyclooxygenase-2 (COX-2) inhibitors; or iii. Anti-histamine use within 24-48 hours of cognitive testing; or iv. Use of topical steroids with a large area of application (more than the size of silver dollar coin); or v. Inhaled steroids taken more than 2-3 times per week.
    • AddedReceived a live vaccine within the last 6 weeks.
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedExecutive Function (TestMyBrain: Choice Reaction Time - Median Response Time on Correct Trials)Time frame: Repeated measures over two weeks
    • RemovedPsychomotor Speed (TestMyBrain: Simple Reaction Time)Time frame: Repeated measures over two weeks
    Secondary outcomes 5 added
    What changed in the outcomes
    • AddedProcessing Speed (TestMyBrain: Matching Shapes and Numbers - Number of Correct Responses)Time frame: Repeated measures over two weeks
    • AddedPsychomotor Speed (TestMyBrain: Fast Reactions - Median Reaction Time)Time frame: Repeated measures over two weeks
    • AddedSelf-reported Depressive Symptom Severity (PROMIS Short Form v1.0 - Depression 4a)Time frame: Repeated measures over two weeks
    • AddedSelf-reported Cognitive Difficulties (PDQ-20: Perceived Deficits Questionnaire)Time frame: Week 2
    • AddedSelf-reported Cognitive Difficulties (PROMIS v2.0 Cognitive Function 8a)Time frame: Week 2
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06136546
Responsible party
Naoise Mac Giollabhui, PhD (Member of the Faculty, Massachusetts General Hospital) — Principal investigator
First posted
Nov 18, 2023
Start date
Jan 23, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Naoise Mac Giollabhui, PhD
Contact
nmacgiollabhui@mgh.harvard.edu
6177241000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infliximab

Start the discussion